Over the past decade, cancer treatments have evolved rapidly, and many cancer patients live longer than ever before. However, cancer mortality remains high, especially among patients with advanced cancer.
At Orion, our goal is to develop new and effective treatments for solid cancers. Our researchers are working to understand the mechanisms behind a patient’s disease and use this knowledge to find new treatments.
In this work, we make extensive use of genetic and molecular data related to solid cancer tumours. Internal and external (immune cell) mechanisms that contribute to cancer tumour growth, resistance to treatments and cancer cell survival are also under investigation.
In addition, it is important to identify patients who will benefit most from treatment and those who may not benefit from it. This can be achieved through various tools such as genome databases, technologies for analysing genetic variables and various data analysis methods.
Our researchers have a long and successful track record of developing innovative oral small-molecule medicines. Today, we also use biological drugs such as antibodies, combinations of antibodies and toxic pharmaceutical ingredients, and CAR-T cells. These allow us to target, as effectively as possible, the mechanisms that are essential for cancer and to reach targets that cannot be reached using small molecules.